BB&T Corp lessened its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 9.3% during the fourth quarter, Holdings Channel reports. The institutional investor owned 4,047 shares of the medical research company’s stock after selling 417 shares during the quarter. BB&T Corp’s holdings in Thermo Fisher Scientific were worth $768,000 as of its most recent SEC filing.
Other institutional investors have also recently made changes to their positions in the company. Amalgamated Bank grew its stake in Thermo Fisher Scientific by 57.0% in the second quarter. Amalgamated Bank now owns 44,921 shares of the medical research company’s stock valued at $7,837,000 after purchasing an additional 16,308 shares in the last quarter. Mutual of America Capital Management LLC grew its stake in Thermo Fisher Scientific by 2.1% in the second quarter. Mutual of America Capital Management LLC now owns 47,728 shares of the medical research company’s stock valued at $8,327,000 after purchasing an additional 977 shares in the last quarter. Americafirst Capital Management LLC bought a new position in Thermo Fisher Scientific in the third quarter valued at approximately $876,000. San Francisco Sentry Investment Group CA bought a new position in Thermo Fisher Scientific in the second quarter valued at approximately $1,451,000. Finally, Huntington National Bank grew its stake in Thermo Fisher Scientific by 2.4% in the third quarter. Huntington National Bank now owns 195,348 shares of the medical research company’s stock valued at $36,959,000 after purchasing an additional 4,655 shares in the last quarter. 86.31% of the stock is currently owned by institutional investors and hedge funds.
TMO has been the subject of several research analyst reports. ValuEngine upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research note on Friday. BTIG Research initiated coverage on Thermo Fisher Scientific in a research note on Friday, January 5th. They set a “buy” rating and a $230.00 target price for the company. Evercore ISI initiated coverage on Thermo Fisher Scientific in a research note on Wednesday, January 3rd. They set an “outperform” rating and a $220.00 target price for the company. Zacks Investment Research downgraded Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research note on Monday, October 30th. Finally, Deutsche Bank set a $226.00 target price on Thermo Fisher Scientific and gave the stock a “buy” rating in a research note on Thursday, October 26th. Two equities research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. Thermo Fisher Scientific currently has an average rating of “Buy” and an average target price of $220.50.
In related news, CEO Marc N. Casper sold 50,000 shares of the business’s stock in a transaction on Friday, December 15th. The stock was sold at an average price of $191.74, for a total value of $9,587,000.00. Following the completion of the sale, the chief executive officer now directly owns 302,577 shares in the company, valued at approximately $58,016,113.98. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.49% of the company’s stock.
Shares of Thermo Fisher Scientific Inc. (NYSE TMO) opened at $208.31 on Tuesday. The stock has a market capitalization of $83,090.00, a price-to-earnings ratio of 37.20, a P/E/G ratio of 1.59 and a beta of 1.11. Thermo Fisher Scientific Inc. has a one year low of $150.39 and a one year high of $226.44. The company has a quick ratio of 0.92, a current ratio of 1.35 and a debt-to-equity ratio of 0.74.
Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, January 31st. The medical research company reported $2.79 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.66 by $0.13. The business had revenue of $6.05 billion during the quarter, compared to the consensus estimate of $5.72 billion. Thermo Fisher Scientific had a return on equity of 16.01% and a net margin of 10.64%. The firm’s quarterly revenue was up 22.1% on a year-over-year basis. During the same period in the previous year, the company posted $2.41 EPS. equities analysts predict that Thermo Fisher Scientific Inc. will post 10.81 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Monday, April 16th. Investors of record on Thursday, March 15th will be paid a $0.17 dividend. The ex-dividend date is Wednesday, March 14th. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.15. This represents a $0.68 annualized dividend and a yield of 0.33%. Thermo Fisher Scientific’s payout ratio is 10.71%.
COPYRIGHT VIOLATION NOTICE: “BB&T Corp Sells 417 Shares of Thermo Fisher Scientific Inc. (TMO)” was first posted by Stock Observer and is owned by of Stock Observer. If you are reading this story on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this story can be read at https://www.thestockobserver.com/2018/02/06/bbt-corp-sells-417-shares-of-thermo-fisher-scientific-inc-tmo.html.
Thermo Fisher Scientific Company Profile
Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.